Physician profile
Danielle Simon
NPI 1013735299
$3,395.52
in general payments reported to CMS, 2019-2025
40 companies · $2,770 in 2025
The $2,770 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $625 · 2025: $2,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,101 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.62 |
| Education | $294.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $318.08 | 2024-2025 | Calquence, Imfinzi, Enhertu |
| Genentech USA, INC. | $251.24 | 2024-2025 | Itovebi, Tecentriq Hybreza, Polivy |
| Abbvie INC. | $238.97 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $195.53 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Astellas Pharma US INC | $183.36 | 2024-2025 | Xospata, Vyloy, Padcev |
| Karyopharm Therapeutics INC. | $138.80 | 2024-2025 | Xpovio |
| Eisai INC. | $138.12 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.27 | 2024-2025 | Ninlaro, Iclusig, Alunbrig |
| Array Biopharma INC | $121.83 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Amgen INC. | $120.10 | 2024 | Lumakras, Imdelltra (Amg 757) |
| Stryker Corporation | $102.27 | 2025 | Augment Injectable |
| Seagen INC. | $99.00 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $90.08 | 2024-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $85.54 | 2025 | Opdivo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.09 | 2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $81.08 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $79.20 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Daiichi Sankyo INC. | $77.16 | 2025 | Enhertu, Datroway |
| Tersera Therapeutics LLC | $71.00 | 2025 | Xermelo |
| Jazz Pharmaceuticals INC. | $58.81 | 2025 | |
| Beone Medicines USA, INC. | $54.80 | 2025 | Brukinsa |
| Lilly USA, LLC | $52.68 | 2025 | Verzenio, Jaypirca |
| Pfizer INC. | $52.68 | 2025 | |
| Adaptive Biotechnologies Corporation | $51.94 | 2025 | Clonoseq |
| Celgene Corporation | $51.80 | 2025 | Reblozyl |
| Glaxosmithkline, LLC. | $50.33 | 2025 | Ojjaara |
| Aveo Pharmaceuticals, INC. | $50.09 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.61 | 2025 | |
| Exelixis INC. | $45.22 | 2025 | Cabometyx |
| Janssen Biotech, INC. | $45.00 | 2025 | Tecvayli, Rybrevant |
| Coherus Oncology, INC. | $33.60 | 2024-2025 | Udenyca |
| Syndax Pharmaceuticals, INC. | $32.98 | 2025 | |
| Geron Corporation | $27.17 | 2025 | Rytelo |
| Servier Pharmaceuticals LLC | $23.87 | 2025 | |
| Incyte Corporation | $22.13 | 2025 | Zynyz, Monjuvi |
| Sobi, INC | $21.50 | 2025 | |
| Adc Therapeutics America, INC. | $19.73 | 2025 | |
| Genmab U.S., INC. | $18.12 | 2024 | Epkinly |
| Acrotech Biopharma INC. | $17.19 | 2024 | Beleodaq |
| Ipsen Biopharmaceuticals, INC | $15.55 | 2025 | Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.